HLD-200 successfully meets primary endpoint in Phase III study

Share this content:
HLD-200 successfully meets primary endpoint in Phase III study
HLD-200 successfully meets primary endpoint in Phase III study
The study, "A Phase III Clinical Endpoint Evaluation Study ("CEES") Examining the Safety and Efficacy of HLD-200 in Pediatric Subjects with Attention-Deficit Hyperactivity Disorder" ("ADHD"), was conducted at four centers in the US. Following a six-week open label, treatment-optimization phase, ...
READ FULL ARTICLE From News Medical
Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

is free, fast, and customized just for you!




Already a member?

Sign In Now »